Clinical characteristics of respiratory tract infection caused by
Klebsiella pneumoniae
case fatality rate
immunocompromised patients
respiratory tract infection
sputum culture
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
01
2023
accepted:
28
07
2023
medline:
5
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
With advancements in medical technology and the growth of an aging society, the number of immunocompromised patients has increased progressively. We retrospectively compared cases of respiratory tract We enrolled 400 immunocompromised patients and 386 immunocompetent patients. Compared to the immunocompetent group, immunocompromised patients were more likely to develop bacteremia and shock and to require mechanical ventilation support during hospitalization. Immunocompromised patients also had a greater probability of polymicrobial infection and a higher rate of antibacterial resistance to carbapenem, which resulted in a higher intensive care unit admission rate, 30-day case fatality rate (CFR), and 6-month CFR. Multivariate analysis indicated that immunocompromised patients with respiratory diseases (odds ratio [OR], 2.189; 95% confidence interval [CI], 1.103-4.344; The disease burden of
Identifiants
pubmed: 37662019
doi: 10.3389/fcimb.2023.1137664
pmc: PMC10469001
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1137664Informations de copyright
Copyright © 2023 Liu, Huang, Cai, Zhu, Li, Yu, Xu, Shi and Feng.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Microbiol Infect. 2015 Apr;21(4):313-22
pubmed: 25753137
Antibiotics (Basel). 2021 Dec 08;10(12):
pubmed: 34943720
Clin Microbiol Infect. 2013 Feb;19(2):187-92
pubmed: 22390624
BMC Infect Dis. 2010 Oct 25;10:307
pubmed: 20973971
BMC Microbiol. 2018 Jan 8;18(1):6
pubmed: 29433440
Infect Dis Ther. 2021 Dec;10(4):2157-2175
pubmed: 34476772
Front Cell Infect Microbiol. 2018 Jan 22;8:4
pubmed: 29404282
Pathogens. 2022 Jun 23;11(7):
pubmed: 35889963
Front Cell Infect Microbiol. 2022 Jun 23;12:903682
pubmed: 35811668
J Clin Microbiol. 2021 Nov 18;59(12):e0021321
pubmed: 34550809
Curr Pharm Biotechnol. 2019;20(4):309-316
pubmed: 30868949
Chest. 2020 Nov;158(5):1896-1911
pubmed: 32561442
Biol Blood Marrow Transplant. 2013 Jan;19(1):102-8
pubmed: 22940054
Clin Infect Dis. 2019 Apr 24;68(9):1482-1493
pubmed: 31222287
Antimicrob Resist Infect Control. 2019 Jan 3;8:1
pubmed: 30622702
Lancet Infect Dis. 2016 Feb;16(2):161-8
pubmed: 26603172
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6115-20
pubmed: 27480857
N Engl J Med. 2014 Mar 27;370(13):1198-208
pubmed: 24670166
Clin Infect Dis. 2022 Sep 29;75(6):1046-1053
pubmed: 35195716
BMC Infect Dis. 2019 Oct 15;19(1):841
pubmed: 31615450
Int J Infect Dis. 2015 Dec;41:29-31
pubmed: 26518064
Front Cell Infect Microbiol. 2017 Nov 21;7:483
pubmed: 29209595
Virulence. 2016 Apr 2;7(3):320-8
pubmed: 26950194
Crit Care. 2011;15(5):R209
pubmed: 21914220
Front Cell Infect Microbiol. 2022 Apr 04;12:796656
pubmed: 35444962
Clin Microbiol Rev. 1998 Oct;11(4):589-603
pubmed: 9767057